References
- Heldal AT, Owe JF, Gilhus NE, et al. Seropositive myasthenia gravis: a nationwide epidemiologic study. Neurology. 2009;73:150–151.
- Lindstrom JM, Seybold ME, Lennon VA, et al. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology. 1976;26:1054–1059.
- Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry. 1985;48:1246–1252.
- Cavalcante P, Bernasconi P, Mantegazza R. Autoimmune mechanisms in myasthenia gravis. Curr Opin Neurol. 2012;25: 621–629.
- Corcoran LM, Tarlinton DM. Regulation of germinal center responses, memory B cells and plasma cell formation-an update. Curr Opin Immunol. 2016;39:59–67.
- Tamura T, Yanai H, Savitsky D, et al. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol. 2008;26:535–584.
- Singh H, Glasmacher E, Chang AB, et al. The molecular choreography of IRF4 and IRF8 with immune system partners. Cold Spring Harb Symp Quant Biol. 2013;78:101–104.
- Lohoff M, Mittrücker HW, Prechtl S, et al. Dysregulated T helper cell differentiation in the absence of interferon regulatory factor 4. Proc Natl Acad Sci USA. 2002;99:11808–11812.
- Brüstle A, Heink S, Huber M, et al. The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat Immunol. 2007;8:958–966.
- Bollig N, Brüstle A, Kellner K, et al. Transcription factor IRF4 determines germinal center formation through follicular T-helper cell differentiation. Proc Natl Acad Sci USA. 2012;109: 8664–8669.
- Huber M, Lohoff M. IRF4 at the crossroads of effector T-cell fate decision. Eur J Immunol. 2014;44:1886–1895.
- Gomez-Rodriguez J, Meylan F, Handon R, et al. Itk is required for Th9 differentiation via TCR-mediated induction of IL-2 and IRF4. Nat Commun. 2016;7:10857.
- Huang SC, Smith AM, Everts B, et al. Metabolic reprogramming mediated by the mTORC2-IRF4 signaling axis is essential for macrophage alternative activation. Immunity. 2016;45: 817–830.
- Lin Q, Chauvistré H, Costa IG, et al. Epigenetic program and transcription factor circuitry of dendritic cell development. Nucleic Acids Res. 2015;43:9680–9693.
- Lee W, Kim HS, Baek SY, et al. Transcription factor IRF8 controls Th1-like regulatory T-cell function. Cell Mol Immunol. 2016;13:785–794.
- Ouyang X, Zhang R, Yang J, et al. Transcription factor IRF8 directs a silencing programme for TH17 cell differentiation. Nat Commun. 2011;2:314.
- Schonheit J, Kuhl C, Gebhardt ML, et al. PU.1 level-directed chromatin structure remodeling at the Irf8 gene drives dendritic cell commitment. Cell Reports. 2013; 3:1617–1628.
- Gupta M, Shin DM, Ramakrishna L, et al. IRF8 directs stress-induced autophagy in macrophages and promotes clearance of Listeria monocytogenes. Nat Commun. 2015;6:6379.
- Sichien D, Scott CL, Martens L, et al. IRF8 transcription factor controls survival and function of terminally differentiated conventional and plasmacytoid dendritic cells, respectively. Immunity. 2016;45:626–640.
- Sciammas R, Shaffer AL, Schatz JH, et al. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity. 2006;25:225–236.
- Klein U, Casola S, Cattoretti G, et al. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol. 2006;7:773–782.
- Ma S, Turetsky A, Trinh L, et al. IFN regulatory factor 4 and 8 promote Ig light chain kappa locus activation in pre-B cell development. J Immunol. 2006;177:7898–7904.
- Lee CH, Melchers M, Wang H, et al. Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence-binding protein. J Exp Med. 2006; 203:63–72.
- Wang H, Lee CH, Qi C, et al. IRF8 regulates B-cell lineage specification, commitment, and differentiation. Blood. 2008;112: 4028–4038.
- Ochiai K, Maienschein-Cline M, Simonetti G, et al. Transcriptional regulation of germinal center B and plasma cell fates by dynamical control of IRF4. Immunity. 2013;38:918–929.
- Carotta S, Willis SN, Hasbold J, et al. The transcription factors IRF8 and PU.1 negatively regulate plasma cell differentiation. J Exp Med. 2014;211:2169–2181.
- Xu H, Chaudhri VK, Wu Z, et al. Regulation of bifurcating B cell trajectories by mutual antagonism between transcription factors IRF4 and IRF8. Nat Immunol. 2015;16:1274–1281.
- Mudter J, Amoussina L, Schenk M, et al. The transcriptionfactor IFN regulatory factor-4 controls experimental colitis in mice viaT cell-derived IL-6. J Clin Invest. 2008;118:2415–2426.
- Biswas PS, Gupta S, Stirzaker RA, et al. Dual regulation of IRF4 function in T and B cells is required for the coordination of T-B cell interactions and the prevention of autoimmunity. J Exp Med. 2012;209:581–596.
- Lessard CJ, Adrianto I, Ice JA, et al. Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. Am J Hum Genet. 2012;90:648–660.
- Chrabot BS, Kariuki SN, Zervou MI, et al. Genetic variation near IRF8 is associated with serologic and cytokine profiles in systemic lupus erythematosus and multiple sclerosis. Genes Immun. 2013;14:471–478.
- Lin JD, Wang YH, Liu CH, et al. Association of IRF8 gene polymorphisms with autoimmune thyroid disease. Eur J Clin Invest. 2015;45:711–719.
- López-Isac E, Martín JE, Assassi S, et al. Brief report: IRF4 newly identified as a common susceptibility locus for systemic sclerosis and rheumatoid arthritis in a cross-disease meta-analysis of genome-wide association studies. Arthritis Rheumatol. 2016;68:2338–2344.
- Jiang Y, Wang H, Yu H, et al. Two genetic variations in the IRF8 region are associated with Behçet’s disease in Han Chinese. Sci Rep. 2016;6:19651.
- Qiao J, Li X, Wu Y, et al. An increased expression profile of Th9/IL-9 correlated with Th17/IL-17 in patients with immune thrombocytopenia. Platelets. 2017;28:287–294.
- Drachman DB. Medical progress: myasthenia gravis. N Engl J Med. 1994;330:1797–1810.
- Jaretzki A III, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55:16–23.
- Sharshar T, Chevret S, Mazighi M, et al. Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis. J Neurol. 2000;247: 286–290.
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–408.
- Xu WH, Zhang AM, Ren MS, et al. Changes of Treg-associated molecules on CD4 + CD25 +Treg cells in myasthenia gravis and effects of immunosuppressants. J Clin Immunol. 2012;32: 975–983.
- Nishimura T, Inaba Y, Nakazawa Y, et al. Reduction in peripheral regulatory T cell population in childhood ocular type myasthenia gravis. Brain Dev. 2015;37:808–816.
- Yu YH, Lin KI. Factors that regulate the generation of antibody-secreting plasma cells. Adv Immunol. 2016;131:61–99.
- Shapiro-Shelef M, Lin K, McHeyzer-Williams LJ, et al. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity. 2003;19:607–620.
- Shaffer AL, Yu X, He Y, et al. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity. 2000;13:199–212.
- Ochiai K, Katoh Y, Ikura T, et al. Plasmacytic transcription factor Blimp-1 is repressed by Bach2 in B cells. J Biol Chem. 2006;281:38226–38234.
- Muto A, Ochiai K, Kimura Y, et al. Bach2 represses plasma cell gene regulatory network in B cells to promote antibody class switch. EMBO J. 2010;29:4048–4061.
- Usui T, Wakatsuki Y, Matsunaga Y, et al. Overexpression of B cell-specific activator protein (BSAP/Pax-5) in a late B cell is sufficient to suppress differentiation to an Ig high producer cell with plasma cell phenotype. J Immunol. 1997;158:3197–3204.
- Lu R. Interferon regulatory factor 4 and 8 in B-cell development. Trends Immunol. 2008;29:487–492.
- Shukla V, Lu R. IRF4 and IRF8: governing the virtues of B lymphocytes. Front Biol. 2014;9:269–282.
- Sciammas R, Davis MM. Modular nature of Blimp-1 in the regulation of gene expression during B cell maturation. J Immunol. 2004;172:5427–5440.
- Chevrier S, Emslie D, Shi W, et al. The BTB-ZF transcription factor Zbtb20 is driven by Irf4 to promote plasma cell differentiation and longevity. J Exp Med. 2014;211:827–840.
- Vander Lugt B, Khan AA, Hackney JA, et al. Transcriptional programming of dendritic cells for enhanced MHC class II antigen presentation. Nat Immunol. 2014;15:161–167.